Securing a positive reimbursement opinion in France is only half the market access battle. Once the Transparency Commission (Commission de la Transparence, or CT) of the Haute Autorité de Santé (HAS) evaluates your medicine, its rating of your product's added clinical value — the ASMR (Amélioration du Service Médical Rendu) — becomes the single most important lever in price negotiations with the CEPS (Comité Économique des Produits de Santé).
For international pharmaceutical and biotech companies used to value-based QALY thresholds in the UK or payer contracting in the US, the French dual rating and negotiation framework can come as a shock. A strong clinical package framed against the wrong comparator can leave a genuinely innovative therapy with an ASMR V — and an automatic demand for a price discount.
This guide walks through how ASMR Levels I to V work in practice, how the CEPS translates those ratings into list and net prices, and how to prepare your negotiation strategy well before your dossier reaches the HAS.
1. SMR vs. ASMR: Why France Separates Reimbursement from Pricing
When your French exploitant or local affiliate submits a reimbursement dossier to the HAS Transparency Commission, the committee issues two distinct ratings in its opinion (avis de la Commission de la Transparence):
- SMR (Service Médical Rendu — Actual Clinical Benefit): Evaluates the absolute medical value of the medicine based on disease severity, efficacy, safety, place in the therapeutic strategy and public health impact. As we explain in our guide to SMR in the French healthcare system, SMR determines whether the product is reimbursed by Assurance Maladie and at what rate (65%, 30%, 15% or 0%).
- ASMR (Amélioration du Service Médical Rendu — Clinical Added Value): Evaluates the relative clinical progress your medicine brings compared with existing clinically relevant treatments on the French market. ASMR determines how your price is negotiated with the CEPS.
In short: SMR opens the door to the reimbursed market; ASMR sets the rules inside the pricing room. You can read the end-to-end procedural sequence in our step-by-step guide to the French reimbursement process.
2. Decoding ASMR Levels I to V (and What Each Rating Means for Your Price)
The Transparency Commission assigns an ASMR on a five-point Roman numeral scale. Each level triggers specific pricing rules under the framework agreement (Accord-Cadre) signed between the CEPS and LEEM (the French pharmaceutical industry association):
- ASMR I (Major progress): Reserved for breakthrough therapies that demonstrate dramatic survival or cure benefits in severe diseases with high unmet need. Only a handful of products achieve ASMR I each decade.
- ASMR II (Important progress): Awarded to therapies showing substantial, clinically meaningful superiority over standard of care on hard clinical endpoints.
- ASMR III (Moderate progress): Recognises clear added clinical benefit — either in efficacy or a major safety advantage — backed by robust comparative data.
- ASMR IV (Minor progress): Indicates a modest but measurable clinical improvement over existing treatments in the indication.
- ASMR V (No clinical added value): The product is considered clinically comparable to available alternatives (or failed to prove superiority due to trial design limitations), even if it received an Important SMR and full reimbursement.
How the CEPS prices each tier
- ASMR I, II and III — The European Price Corridor Guarantee: Products awarded ASMR I to III are entitled to a list price consistent with prices in the four main European reference countries (Germany, Italy, Spain and the UK). Under the Accord-Cadre, the CEPS guarantees a published price no lower than the lowest price among those four markets, typically alongside a multi-year price stability protection.
- ASMR IV — Comparator Plus or Parity Pricing: Pricing is anchored to the daily or course treatment cost of the French clinical comparator, with scope for a modest premium if strong health-economic or organizational benefits are demonstrated, or reference to European prices in specific cases.
- ASMR V — Mandatory Cost Savings by Law: Under Article L.162-16-4 of the French Social Security Code, a medicine with an ASMR V cannot be listed on the retail reimbursement list (liste des spécialités remboursables aux assurés sociaux) unless it generates a reduction in treatment cost compared with the comparator, unless there is a formal public health need to avoid a class shortage.
Why this matters: More than 60% of initial HAS assessments result in an ASMR V. International teams that budget for a German-level price without securing at least an ASMR III or IV face a painful commercial reset. It is one of the top mistakes pharma companies make when entering France.
3. Choosing the Right Clinical Comparator Before You Submit to the HAS
The Transparency Commission does not evaluate your product in a vacuum. It asks one central question: how does this medicine perform against the clinically relevant comparator (comparateur cliniquement pertinent, or CCP) currently used in French clinical practice?
Three methodology traps routinely downgrade promising medicines to ASMR IV or V:
- Placebo-controlled trials when an active standard of care exists in France: Even if the EMA accepted a placebo-controlled pivotal trial for regulatory approval, the HAS will heavily penalise the absence of a direct head-to-head comparison against the French standard of care.
- Using a US comparator that is not reimbursed or widely used in France: If your global Phase III trial compared your drug against an agent that lacks reimbursement or routine adoption in French hospitals, you will need a rigorous indirect treatment comparison (ITC) — and the CT applies strict methodological scrutiny to network meta-analyses and matching-adjusted indirect comparisons.
- Surrogate endpoints without validated clinical translation: Unless a surrogate endpoint is firmly established as predicting overall survival or morbidity, or paired with robust quality-of-life (QoL) data collected with validated scales, the CT rarely awards ASMR I–III.
Mapping real-world French clinical pathways and prescribing habits 12 to 18 months before submission — through structured patient journey and stakeholder mapping — lets you anticipate which comparators the CT will select and build the right sub-population strategy.
4. Inside the CEPS Negotiation Room: List Price, Confidential Rebates and Volume Clauses
Once the HAS publishes its CT opinion (and, for innovative products with an ASMR I–III Request and significant budget impact, an economic evaluation opinion from the CEESP), your dossier moves to the CEPS. The CEPS is an inter-ministerial committee bringing together officials from the Ministries of Health, Social Security, and Economy alongside statutory health insurance funds (UNCAM) and complementary insurers (UNOCAM).
CEPS negotiations are contractual and culminate in a multi-year agreement (convention) signed by your company or exploitant. Key mechanisms at the table include:
- Published List Price (Prix Facial) vs. Confidential Net Price: For products subject to international reference pricing (IRP) across Europe and beyond, preserving a high public list price in the Journal Officiel is critical. The CEPS frequently agrees to a higher published list price paired with a confidential unit rebate (remise par boîte) paid back to Assurance Maladie.
- Price-Volume Agreements (Clauses de Volume): The CEPS places heavy emphasis on budget predictability. Your convention will almost always set annual net revenue caps by indication, with tiered rebates triggered automatically if actual sales exceed the agreed forecast.
- Performance and Real-World Evidence Clauses: Where clinical uncertainty remains at launch, the CEPS may tie price maintenance or rebate levels to post-launch real-world cohorts or re-evaluation milestones.
- Sectoral Clawbacks (Clause de Sauvegarde / M-Tax): Beyond product-specific rebates, companies operating in France must model industry-wide turnover taxes and safeguard clawbacks when net national pharmaceutical spending exceeds the annual Parliament-voted target (ONDAM). You can model these commercial and operational variables in our France Launch Cost Calculator.
5. How Early Access (Accès Précoce) and Hospital Listing Shape Your Negotiation Leverage
For severe, rare or disabling conditions with no appropriate treatment in France and an urgent need to treat, France's Accès Précoce (Early Access) programme changes both launch timing and pricing dynamics:
- Free pricing indemnity during Accès Précoce: While under Accès Précoce, the company sets its maximum indemnity price freely, generating immediate revenue and early physician experience in French reference centres.
- Retroactive clawback once the CEPS price is agreed: Once standard reimbursement and the final CEPS net price are signed, the difference between the free Accès Précoce indemnity and the final negotiated net price is paid back retroactively — alongside annual turnover cap rebates during the early access period.
- Hospital Liste en Sus eligibility: For expensive hospital-administered therapies, securing at least an ASMR I to III (or ASMR IV in specific justified cases against a liste en sus comparator) is essential to be funded on top of standard hospital DRG tariffs (tarifs des GHS). Without liste en sus status, hospitals must absorb the drug cost out of their routine procedure budget, which severely restricts uptake.
6. A Practical Checklist Before Entering HAS and CEPS Discussions
Whether you are 18 months from EMA approval or preparing your national transparency dossier right now, run through these six steps:
- Audit your French comparator early: Verify what French clinicians actually prescribe in each line of therapy and how the CT rated recent entrants in your indication.
- Prioritise the sub-population where your clinical delta is strongest: Sometimes seeking reimbursement initially in a narrower, high-unmet-need population secures an ASMR III or IV instead of a broad ASMR V.
- Coordinate European launch sequencing: If you are targeting an ASMR I–III, know what prices will be visible in Germany, Italy, Spain and the UK when the CEPS checks the European corridor.
- Build a realistic 3- to 5-year French epidemiology and volume model: Over-optimistic volume forecasts can backfire if they trigger aggressive upfront price cuts from the CEPS; under-forecasting triggers steep volume clawbacks.
- Ensure your French exploitant is aligned early: The exploitant is central to supply commitments, Accès Précoce data collection, and regulatory compliance throughout the lifecycle.
- Align your medical, market access and French field team strategy: The therapeutic positioning approved in your HAS Transparency opinion directly governs what your ANSM promotional visa PM will allow your representatives and KAMs to say.
Why Elliogen?
At Elliogen, we help international pharma and biotech companies bridge the gap between global clinical data and French market access reality. From early patient pathway and stakeholder mapping to HAS/CEPS market access strategy, free exploitant partner matching, and commercial launch execution, we connect you with the right French specialists under one coordinated plan.
If you want an honest assessment of what ASMR rating your product is likely to achieve in France — and how to structure your CEPS pricing and launch roadmap — let's talk.
👉 Book a Free 20-Minute Consultation or email us at hello@elliogen.com
FAQ
- What is the difference between SMR and ASMR in France? SMR (Service Médical Rendu) measures absolute clinical benefit and determines whether a drug is reimbursed and at what percentage. ASMR (Amélioration du Service Médical Rendu) measures relative added clinical value (Levels I to V) against existing treatments and drives price negotiations with the CEPS.
- Can a drug with an ASMR V still be reimbursed in France? Yes. Many drugs with an Important SMR receive 65% reimbursement alongside an ASMR V. However, by law an ASMR V product must generally be priced lower than its clinical comparator on the retail market.
- How long do HAS evaluation and CEPS price negotiations take? While the statutory EU Transparency Directive clock is 180 days, the combined HAS evaluation and CEPS negotiation in France typically takes 9 to 15 months for new active substances unless bridged by an Accès Précoce programme.
- Are CEPS rebates public in France? No. The published list price (prix facial) appears in the Journal Officiel, while product-specific rebates (remises) and price-volume terms negotiated with the CEPS remain strictly confidential under commercial secrecy laws.